Fungal infection incidents are reported to be increasing dramatically each year, likely a result of an aging population and an increase in organ transplant cases which combined have increased the total number of immuno-compromised persons in society.
However, the currently available antifungal agents have limits to their effectiveness and have safety concerns related to their long term usage.
In light of these facts, there exists a need for a new antifungal agent with a much better safety profile (with a reduced number of side effects).
ANTIFUNGAL AGENT DEVELOPMENT
By iNtRON Biotechnology
iNtRON Bio is developing a new type of antifungal agent which has a polyketide structure and is labeled iN-EYD34.
iN-EYD34 has a fundamentally different mode of action, and has a safer profile compared to preexisting commonly used antifungal agents (e.g. polyene and azole).
iN-EYD34 has demonstrated powerful antifungal activity against a number of clinical isolates including Cryptococcus neoformans and Candida albicans.
iN-EYD34 proved to be highly safe in animal toxicity tests.
According to the BCC Research report (2014) entitled “Antifungal drug: Technologies and Global Markets”, the global market for human antifungal agents reached nearly $11.6 billion in 2012 and $11.8 billion in 2013.
This market is expected to grow to nearly $13.9 billion in 2018 with a compound annual growth rate (CAGR) of 3.2% over the five-year period from 2013 to 2018.
The U.S. human antifungal agent market reached nearly $4.9 billion in 2013. It is projected to grow to $5.5 billion in 2018 with a CAGR of 2.7% over the five-year period from 2013 to 2018.
The Europe human antifungal agent market reached $3.9 billion in 2013. It is projected to grow to $4.4 billion in 2018 with a CAGR of 2.6% over the five-year period from 2013 to 2018.